How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia

• Published in: Cancers Vol. 15; no. 11; p. 2991
• Main Authors: Haage, Tobias R, Schraven, Burkhart, Mougiakakos, Dimitrios, Fischer, Thomas
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.05.2023; MDPI
• Subjects: Acute myeloid leukemia; Antimitotic agents; Antineoplastic agents; Binding sites; Bone marrow; Cancer; Chemotherapy; Cytokines; FDA approval; FLT3 gene; Gene mutations; Genetic aspects; Genotypes; Insertion; Kinases; Leukemia; Ligands; Localization; Mutation; Phosphorylation; Protein-tyrosine kinase; Proteins; Remission; Review; Tyrosine; Germany; non-juxtamembrane domain (non-JMD) insertion site; chemotherapy resistance; acute myeloid leukemia (AML); internal tandem duplications (FLT3-ITD); tyrosine kinase inhibition (TKI); FLT3 mutation
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15112991

Mutations of the gene are among the most common genetic aberrations detected in AML and occur mainly as internal tandem duplications (FLT3-ITD). However, the specific sites of FLT3-ITD insertion within show marked heterogeneity regarding both biological and clinical features. In contrast to the common assumption that ITD insertion sites (IS) are restricted to the juxtamembrane domain (JMD) of FLT3, 30% of FLT3-ITD mutations insert at the non-JMD level, thereby integrating into various segments of the tyrosine kinase subdomain 1 (TKD1). ITDs inserted within TKD1 have been shown to be associated with inferior complete remission rates as well as shorter relapse-free and overall survival. Furthermore, resistance to chemotherapy and tyrosine kinase inhibition (TKI) is linked to non-JMD IS. Although FLT3-ITD mutations in general are already recognized as a negative prognostic marker in currently used risk stratification guidelines, the even worse prognostic impact of non-JMD-inserting FLT3-ITD has not yet been particularly considered. Recently, the molecular and biological assessment of TKI resistance highlighted the pivotal role of activated WEE1 kinase in non-JMD-inserting ITDs. Overcoming therapy resistance in non-JMD FLT3-ITD-mutated AML may lead to more effective genotype- and patient-specific treatment approaches.